Evidence map›Paper›PMID 40828419›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2025

Rafting toward a depression biomarker.

Mark M Rasenick

Abstract readPersonal Narrative
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mark M RasenickPsychiatry and Physiology, University ofIllinois College of Medicine, Jesse Brown VAMC, Chicago, IL, 60612, USA. raz@uic.edu.ORCID http://orcid.org/0000-0003-2405-4364

Funding

Using a novel model of antidepressant efficacy to discover new compounds and personalized treatments.R41MH113398 · NIMH · PAX NEUROSCIENCE, INC. · PI RASENICK, MARK M. · 2017 to 2018
$871k
BLRD VA I01 BX001149BLRD VA IK6 BX004475NIMH NIH HHS R41 MH113398NIMH NIH HHS R41MH113398U.S. Department of Veterans Affairs BX001149U.S. Department of Veterans Affairs BX04475
6 · The paper itself

Abstract

The journey from the cytoskeleton and G protein signaling to a framework that might provide a simple blood diagnostic for depression as well as a harbinger of individual antidepressant response, has been convoluted, occasionally frustrating, but ultimately rewarding. Herein, I provide a travelogue of sorts on our progress toward this end, and also chart a course toward the goal of providing a simple, quantitative and objective, biomarker-driven assessment tool that reflects the neurobiology of depressed mood.

Indexed as

Antidepressive AgentsBiomarkersDepressionDepressive DisorderMembrane MicrodomainsHumansAntidepressive AgentsBiomarkersAntidepressantcAMPGPCRG proteinLlipid raft

Identifiers

PMID40828419
PMCPMC12500797

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.